Physician profile
Kiley Cook
NPI 1083294433
$7,783.65
in general payments reported to CMS, 2019-2025
36 companies · $2,386 in 2025
The $2,386 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,153 · 2023: $1,501 · 2024: $2,744 · 2025: $2,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,630.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,679.60 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,336.65 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,004.86 | 2022-2025 | |
| Glaxosmithkline, LLC. | $615.79 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $525.92 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $436.63 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $405.78 | 2023-2025 | |
| Abiomed | $277.13 | 2024 | Impella |
| Shield Therapeutics INC | $209.94 | 2023-2025 | Accrufer |
| Viiv Healthcare Company | $135.93 | 2024-2025 | Apretude |
| Axsome Therapeutics, INC. | $135.66 | 2025 | Symbravo, Auvelity |
| Supernus Pharmaceuticals, INC. | $108.90 | 2025 | Qelbree |
| Dexcom, INC. | $103.70 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $88.02 | 2023-2025 | Capvaxive, Gardasil 9, Gardasil |
| Sunovion Pharmaceuticals INC. | $65.40 | 2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiley Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.